GlassScriptPhysician profile
Scott R Gutowski
NPI 1689690158
$13,118.09
in general payments reported to CMS, 2019-2025
49 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $1,270 · 2021: $2,377 · 2022: $2,362 · 2023: $2,306 · 2024: $1,904 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,155 · Education: $71.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,154.88 |
| Education | $71.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,938.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,042.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,001.97 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $934.45 | 2022-2025 | Rexulti |
| Abbvie INC. | $832.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $793.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $725.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $554.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $529.69 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Amgen INC. | $476.50 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $430.74 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $348.23 | 2020-2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $259.60 | 2022-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.80 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Dexcom, INC. | $228.08 | 2021-2025 | Dexcom G6 Transmitter |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gutowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.